

**EPF wishes to thank the European Commission /European Agencies** for their support in 2020 in relation to EPF's role in the following projects

	Public Contribution 2020	% of total income
<b>TOTAL European Commission support to projects 2020</b>	<b>€ 494,674.93</b>	
CHRODIS +	€ 32,198.85	1.4%
ComparEU	€ 35,441.74	1.5%
DigitalHealthEurope	€ 62,635.75	2.7%
EATRIS +	€ 11,262.66	0.5%
EFO EUPATI	€ 92,968.58	4.0%
EHDEN	€ 23,753.40	1.0%
EUPATI Reloaded (EIT)	€ 50,000.00	2.2%
EU-PEARL	€ 30,641.48	1.3%
Gravitate Health	€ 5,768.54	0.2%
H2O	€ 6,610.90	0.3%
IMMUCAN	€ 19,408.57	0.8%
Pharmaledger	€ 5,822.88	0.3%
PERISCOPE	€ 1,675.83	0.1%
PERMIT	€ 10,886.01	0.5%
PREFER	€ 2,799.79	0.1%
VAC-PACT	€ 102,799.98	4.4%

**EPF wishes to thank the following donors** for their support:

	Contribution to Operations	% of total income
<b>Operational &amp; Engagement - work plan 2020/ Project Development 2020</b>	<b>€ 706,400.00</b>	
AbbVie	€ 35,000.00	1.5%
Amgen	€ 35,000.00	1.5%
Astellas	€ 15,000.00	0.6%
BMS	€ 50,000.00	2.2%
CSL Behring	€ 10,000.00	0.4%
Edwards Lifescience SA	€ 25,000.00	1.1%
Grunenthal	€ 5,000.00	0.2%
GSK	€ 30,000.00	1.3%
Janssen	€ 50,000.00	2.2%
LEO Pharma	€ 10,000.00	0.4%
Medicines for Europe	€ 20,000.00	0.9%
Merck	€ 35,000.00	1.5%
MSD	€ 67,500.00	2.9%
Novartis Pharma AG	€ 100,000.00	4.3%
Pfizer SANV	€ 25,000.00	1.1%
Philips	€ 10,000.00	0.4%
F. Hoffman-La Roche	€ 50,000.00	2.2%
Sanofi Aventis	€ 50,000.00	2.2%
Takeda	€ 30,000.00	1.3%
UCB	€ 25,000.00	1.1%
Vertex	€ 10,000.00	0.4%
Membership	€ 18,900.00	0.8%

<b>Capacity Building Programme 2020</b>	<b>€ 400,375.68</b>	
	Contribution to the CBP	% of total income
Alexion	€ 13,800.00	0.6%
Astellas	€ 15,000.00	0.6%
Baxter	€ 10,000.00	0.4%
EFPIA (DSL)	€ 151,575.68	6.5%
EIT Health (DSL)	€ 25,000.00	1.1%
ENHA (ILC)	€ 10,000.00	0.4%
Gilead Sciences Europe	€ 25,000.00	1.1%
GSK	€ 30,000.00	1.3%
Kyowa Kirin	€ 35,000.00	1.5%
LEO Pharma	€ 15,000.00	0.6%
Medtech (DSL)	€ 10,000.00	0.4%
MSD	€ 20,000.00	0.9%
Pfizer Inc	€ 25,000.00	1.1%
Servier	€ 15,000.00	0.6%

<b>Congress 2021</b>	€	<b>30,000.00</b>	
		Contribution to CGS	% of total income
Fresenius-Kabi	€	10,000.00	0.4%
Novo Nordisk	€	20,000.00	0.9%
<b>Patients Active in Research and Dialogue for an Improved Generation of Medicine "PARADIGM"</b>	€	<b>322,025.38</b>	
			% of total income
Innovative Medicines Initiative (IMI JU) PARADIGM EC Funding	€	212,504.55	9.2%
<b>Industry</b> cash contribution (Amgen, Lundbeck, MSD, Pfizer, VFA)	€	109,520.83	4.7%
<b>Patient Academy on Therapeutic Innovation "EUPATI Programme"</b>	€	<b>293,805.01</b>	
			% of total income
Industry consortium (AbbVie, Amgen, AstraZeneca UK, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DIA, F. Hoffmann-La Roche, GSK, Janssen, LEO Pharma, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Shire, UCB, Takeda, VFA)	€	293,805.01	12.7%
<b>EFOEUPATI</b>	€	<b>20,000.00</b>	
			% of total income
Industry cash contribution (Novartis)	€	20,000.00	0.9%
<b>Other income (including reserves)</b>	€	<b>53,833.21</b>	2.3%
<b>Total Income</b>	€	<b>2,321,114.21</b>	
Accrual and deferrals	-€	107,220.98	
<b>Total Income net of adjustments</b>	€	<b>2,213,893.23</b>	

<b>EPF Funding Transparency (Jan - Dec 2020)</b>	
Overall proportion of Industry and non-industry income	Private: 66.4% Public: 33.6%
Percentage of the highest contribution from a single Industry Donor	EFPIA 6.5%
Percentage of the highest contribution from a single Industry Company	Novartis 4.3%